Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Astellas Pharma
Biotech
Astellas stops development of early-stage lymphoma CAR-T
Astellas has called it quits on the development of a CAR-T asset in lymphoma. The therapy leveraged technology from Astellas' subsidiary Xyphos.
Fraiser Kansteiner
Jan 9, 2025 6:49am
Astellas pays Sangamo $20M to boost neurological gene therapies
Dec 19, 2024 7:13am
Astellas telegraphs new cell therapy site in Japan, 24 US layoffs
Oct 9, 2024 5:45pm
Astellas pays $50M for option on AviadoBio dementia gene therapy
Oct 8, 2024 7:40am
Astellas’ new lab zooms in on targeted protein degradation
Sep 5, 2024 12:01pm
ASCO: It's back to the basics for cancer drug developers
Jun 5, 2024 10:55am
